Subcellular markers will be assessed in relationship to cellular acute rejection in de novo cardiac transplant recipients receiving either tacrolimus or cyclosporine as their primary immunosuppressant~Two parallel active arms.
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.